Show Summary Details
Page of

The future of gout management 

The future of gout management
The future of gout management

Nicola Dalbeth

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 03 December 2021

At present, despite the increasing prevalence of the disease, gout is poorly treated. Alternative models of care within primary care offer new opportunities for effective gout management. In addition to more effective use of approved agents, future gout management will be improved with increasing availability of new urate-lowering drugs. The role of urate-lowering therapy for asymptomatic hyperuricaemia, particularly in the context of co-morbid conditions such as chronic kidney disease, hypertension, and coronary artery disease is currently unknown; large clinical trials are needed to address this key question. Wider and earlier adoption of urate-lowering therapy in those with established gout is likely to reduce the long-term impact of this common condition.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.